相似文献
1
Genetic basis of pancreas cancer development and progression: insights from whole-exome and whole-genome sequencing.
Clin Cancer Res. 2012 Aug 15;18(16):4257-65. doi: 10.1158/1078-0432.CCR-12-0315.
2
The genetic classification of pancreatic neoplasia.
J Gastroenterol. 2015 May;50(5):520-32. doi: 10.1007/s00535-015-1037-4. Epub 2015 Jan 21.
3
Genetic evolution of pancreatic cancer: lessons learnt from the pancreatic cancer genome sequencing project.
Gut. 2012 Jul;61(7):1085-94. doi: 10.1136/gut.2010.236026. Epub 2011 Jul 11.
4
Exome sequencing and digital PCR analyses reveal novel mutated genes related to the metastasis of pancreatic ductal adenocarcinoma.
Cancer Biol Ther. 2012 Aug;13(10):871-9. doi: 10.4161/cbt.20839. Epub 2012 Aug 1.
5
Pathways of Progression From Intraductal Papillary Mucinous Neoplasm to Pancreatic Ductal Adenocarcinoma Based on Molecular Features.
Gastroenterology. 2019 Feb;156(3):647-661.e2. doi: 10.1053/j.gastro.2018.10.029. Epub 2018 Oct 17.
6
The molecular genetics of pancreatic ductal carcinoma.
Minerva Chir. 2002 Oct;57(5):561-74.
7
Precancerous neoplastic cells can move through the pancreatic ductal system.
Nature. 2018 Sep;561(7722):201-205. doi: 10.1038/s41586-018-0481-8. Epub 2018 Sep 3.
8
Where and when does pancreatic carcinoma start?
Med Klin (Munich). 2004 Apr 15;99(4):191-5. doi: 10.1007/s00063-004-1028-3.
9
Pancreatic adenocarcinoma with a germline PTEN p.Arg234Gln mutation.
Fam Cancer. 2018 Apr;17(2):255-259. doi: 10.1007/s10689-017-0025-7.
10
Serine/Threonine Kinase and its Role in Pancreatic Risk.
Genes (Basel). 2020 Jan 17;11(1):108. doi: 10.3390/genes11010108.
引用本文的文献
1
Oncolytic viral therapy as a novel potential solution for treatment of pancreatic cancer.
Gastroenterol Hepatol Bed Bench. 2025;18(1):53-69. doi: 10.22037/ghfbb.v18i1.3066.
2
Efficient and multiplexed somatic genome editing with Cas12a mice.
Nat Biomed Eng. 2025 May 30. doi: 10.1038/s41551-025-01407-7.
3
Survey for Activating Oncogenic Mutation Variants in Metazoan Germline Genes.
J Mol Evol. 2024 Dec;92(6):930-943. doi: 10.1007/s00239-024-10218-4. Epub 2024 Nov 26.
4
Resistance to gemcitabine is mediated by the circ_0036627/miR-145/S100A16 axis in pancreatic cancer.
J Cell Mol Med. 2024 Jun;28(12):e18444. doi: 10.1111/jcmm.18444.
5
REV7 is involved in outcomes of platinum-based chemotherapy in pancreatic cancer by controlling the DNA damage response.
Cancer Sci. 2024 Feb;115(2):660-671. doi: 10.1111/cas.16044. Epub 2023 Dec 21.
6
Whole-exome sequencing of calcitonin-producing pancreatic neuroendocrine neoplasms indicates a unique molecular signature.
Front Oncol. 2023 Sep 12;13:1160921. doi: 10.3389/fonc.2023.1160921. eCollection 2023.
7
Advances in Pancreatic Cancer Treatment by Nano-Based Drug Delivery Systems.
Pharmaceutics. 2023 Sep 21;15(9):2363. doi: 10.3390/pharmaceutics15092363.
8
Prognostic-related genes for pancreatic cancer typing and immunotherapy response prediction based on single-cell sequencing data and bulk sequencing data.
Oncol Res. 2023 Jul 21;31(5):697-714. doi: 10.32604/or.2023.029458. eCollection 2023.
9
Preferential killing of melanoma cells by a p16-related peptide.
Biol Open. 2023 Aug 15;12(8). doi: 10.1242/bio.059965. Epub 2023 Aug 17.
10
Morphology-guided transcriptomic analysis of human pancreatic cancer organoids reveals microenvironmental signals that enhance invasion.
J Clin Invest. 2023 Apr 17;133(8):e162054. doi: 10.1172/JCI162054.
本文引用的文献
1
Conceptual framework for cutting the pancreatic cancer fuel supply.
Clin Cancer Res. 2012 Aug 15;18(16):4285-90. doi: 10.1158/1078-0432.CCR-12-0041.
2
Heterogeneity and targeting of pancreatic cancer stem cells.
Clin Cancer Res. 2012 Aug 15;18(16):4277-84. doi: 10.1158/1078-0432.CCR-11-3112.
3
The pancreas cancer microenvironment.
Clin Cancer Res. 2012 Aug 15;18(16):4266-76. doi: 10.1158/1078-0432.CCR-11-3114.
4
ATM mutations in patients with hereditary pancreatic cancer.
Cancer Discov. 2012 Jan;2(1):41-6. doi: 10.1158/2159-8290.CD-11-0194. Epub 2011 Dec 29.
5
Computational modeling of pancreatic cancer reveals kinetics of metastasis suggesting optimum treatment strategies.
Cell. 2012 Jan 20;148(1-2):362-75. doi: 10.1016/j.cell.2011.11.060.
6
Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia.
Gastroenterology. 2012 Apr;142(4):730-733.e9. doi: 10.1053/j.gastro.2011.12.042. Epub 2012 Jan 5.
7
Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways.
Proc Natl Acad Sci U S A. 2011 Dec 27;108(52):21188-93. doi: 10.1073/pnas.1118046108. Epub 2011 Dec 8.
8
Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development.
Sci Transl Med. 2011 Jul 20;3(92):92ra66. doi: 10.1126/scitranslmed.3002543.
9
Altered telomeres in tumors with ATRX and DAXX mutations.
Science. 2011 Jul 22;333(6041):425. doi: 10.1126/science.1207313. Epub 2011 Jun 30.
10
Everolimus for advanced pancreatic neuroendocrine tumors.
N Engl J Med. 2011 Feb 10;364(6):514-23. doi: 10.1056/NEJMoa1009290.
Zotero 插件